{"id":905438,"date":"2025-11-04T17:32:41","date_gmt":"2025-11-04T22:32:41","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/omniab-reports-third-quarter-2025-financial-results-and-business-highlights\/"},"modified":"2025-11-04T17:32:41","modified_gmt":"2025-11-04T22:32:41","slug":"omniab-reports-third-quarter-2025-financial-results-and-business-highlights","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/omniab-reports-third-quarter-2025-financial-results-and-business-highlights\/","title":{"rendered":"OmniAb Reports Third Quarter 2025 Financial Results and Business Highlights"},"content":{"rendered":"

<\/p>\n

OmniAb Reports Third Quarter 2025 Financial Results and Business Highlights<\/b><\/p>\n

Conference Call with Slides Begins at 4:30 p.m. Eastern Time Today<\/i><\/b><\/p>\n

EMERYVILLE, Calif.–(BUSINESS WIRE<\/a>)–OmniAb, Inc. (NASDAQ: OABI) <\/b>today reported financial results for the three and nine months ended September 30, 2025, and provided operating and partner program updates.\n<\/p>\n

\n\u201cThroughout the third quarter we continued to execute on our strategic initiatives while further demonstrating the value of our proprietary technology platform to a growing base of partners. The number of new program additions so far this year has significantly outpaced last year, bolstering our partnered pipeline and creating potential sources of enduring value within our portfolio. Importantly, OmniAb\u2019s innovative technology platform and operational model allow for partner and program additions within an increasingly efficient and lean cost structure,\u201d said Matt Foehr, Chief Executive Officer of OmniAb. “In August we completed a private placement and strengthened our balance sheet while continuing to expand our suite of leading-edge technologies. We look forward to next month\u2019s launch of OmniUltra\u2122<\/sup>, an important new technology that we expect will expand our platform and open new business opportunities.\u201d\n<\/p>\n

Third Quarter 2025 Financial Results<\/b><\/p>\n

\nRevenue for the third quarter of 2025 was $2.2 million, compared with $4.2 million for the same period in 2024, with the decrease primarily related to lower milestone revenue and a decline in service revenue associated with the completion of work on certain small molecule ion channel programs earlier this year.\n<\/p>\n

\nResearch and development expense was $10.4 million for the third quarter of 2025, compared with $13.3 million for the same period in 2024, with the decrease primarily due to lower personnel expenses related to reduced share-based compensation expense and headcount, and lower external expenses associated with small molecule ion channel programs. General and administrative expense was $6.8 million for the third quarter of 2025, compared with $7.1 million for the same period in 2024, with the decrease primarily due to lower legal fees and share-based compensation expense.\n<\/p>\n

\nNet loss for the third quarter of 2025 was $16.5 million, or $0.14 per share, compared with a net loss of $16.4 million, or $0.16 per share, for the same period in 2024.\n<\/p>\n

Nine Months Ended September 30, 2025 Financial Results<\/b><\/p>\n

\nRevenue for the nine months ended September 30, 2025 was $10.3 million, compared with $15.6 million for the same period in 2024. The decline in license and milestone revenue was primarily due to lower milestone revenue, and service revenue declined primarily as a result of the completion or discontinuation of certain small molecule ion channel programs and the acceleration of revenue in the prior-year period from one of the discontinued programs. These decreases were offset by $0.7 million in xPloration revenue reflecting the sale of an instrument and related consumables.\n<\/p>\n

\nCost of xPloration revenue was $0.3 million for the nine months ended September 30, 2025 and consisted of direct costs associated with the sale of the xPloration instrument and associated consumables. Research and development expense was $33.8 million for the nine months ended September 30, 2025, compared with $41.8 million for the same period in 2024, primarily due to lower personnel expenses and lower external expenses associated with ion channel programs and contract research costs. General and administrative expense was $22.4 million for the nine months ended September 30, 2025, compared with $23.4 million for the same period in 2024 with the decrease primarily due to lower legal fees and share-based compensation expense. Other operating income, net for the nine months ended September 30, 2025 was $2.7 million and reflected a gain of $3.0 million from the sale of a small molecule Kv7.2 program to Angelini and a $0.9 million reduction in contingent liabilities attributed to changes in certain ion channel programs, partially offset by the $1.0 million contingent liability adjustment associated with the Angelini program. Other operating income, net during the nine months ended September 30, 2024 was $2.3 million and included a $2.4 million reduction in contingent liabilities primarily attributed to changes in ion channel programs.\n<\/p>\n

\nNet loss for the nine months ended September 30, 2025 was $50.6 million, or $0.46 per share, compared with a net loss of $49.0 million, or $0.48 per share, for the same period in 2024.\n<\/p>\n

\nAs of September 30, 2025, OmniAb had cash, cash equivalents and short-term investments of $59.5 million. In August, OmniAb raised $30 million from a private placement of common stock, with net proceeds to the Company of approximately $28 million.\n<\/p>\n

2025 Financial Guidance<\/b><\/p>\n

\nOmniAb now expects 2025 revenue to be in the range of $18 million to $22 million, and operating expense to be in the range of $82 million to $86 million. In addition, OmniAb continues to expect 2025 cash use to be lower than cash use in 2024, excluding financings. The Company expects to end the year with cash between $52 million and $56 million. The 2025 full year effective tax rate is expected to be approximately 0%.\n<\/p>\n

Third Quarter 2025 and Recent Business Highlights<\/b><\/p>\n

\nDuring the third quarter of 2025, OmniAb entered into new license agreements, including with A*Star and University of Leeds, and recently with Dana-Farber Cancer Institute, Inc. As of September 30, 2025, the Company had 104 active partners and 399 active programs, including 32 OmniAb-derived programs in clinical development or being commercialized.\n<\/p>\n

\nOmniAb continued to expand its intellectual property portfolio with the issuance of a U.S. patent related to its new OmniUltra\u2122 technology, a transgenic chicken that produces a cow-like antibody with an exceptionally long third heavy-chain complementarity-determining region (CDRH3). The Company plans to launch this new proprietary discovery platform in December 2025 at the Antibody Engineering & Therapeutics (AET) conference in San Diego.\n<\/p>\n

\nIn addition, OmniAb and GSK published a paper titled \u201cVoltage sensor interaction site for a selective small molecule Nav1.1 sodium channel potentiator that enhances firing of fast-spiking interneurons<\/a>\u201d in the October 2025 edition of Molecular Pharmacology<\/i>. The paper highlights the potential for Nav1.1 as a therapeutic target for seizure disorders.\n<\/p>\n

\nBusiness and partner highlights from the third quarter of 2025 and recent weeks included the following:\n<\/p>\n

Batoclimab & IMVT-1402<\/span><\/p>\n